1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 0 to 30
Sponsor: Other
Protocol IDs: EUDRACT 2005-002618-40, BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 21 at diagnosis
Sponsor: NCI
Protocol IDs: COG-ACNS0331, ACNS0331, NCT00085735
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 21 at diagnosis
Sponsor: NCI
Protocol IDs: SJCRH-SJMB03, NCT00085202
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 18
Sponsor: Other
Protocol IDs: GPOH-HIT-GBM-D, EU-205100, NCT00278278
|
|
5.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 3
Sponsor: NCI
Protocol IDs: COG-ACNS0334, ACNS0334, NCT00336024
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 10 at diagnosis
Sponsor: Other
Protocol IDs: CHLA-HEAD-START-III, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI
Protocol IDs: COG-ACNS0332, ACNS0332, NCT00392327
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0398, NCT00500890
|
|
9.
|
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 3 to 25
Sponsor: Other
Protocol IDs: SCRT Trial, NCT00517959
|
|
10.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to 18
Sponsor: NCI
Protocol IDs: COG-ACCL0431, ACCL0431, NCT00716976
|
|
11.
|
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: Under 3
Sponsor: Other
Protocol IDs: CCLG-CNS-2007-09, CCLG CNS 2007 09, EU-20835, NCT00683319
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2301, NCT00789828
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: SJCRH-SJHG04, GENENTECH-OSI3160s, NCT00124657
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Other
Protocol IDs: CNS 0201, NCT00179907
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: SUN08-01, NCT00704054
|
|
17.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: BC-BT-10, NCT00003458
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: BC-BT-12, NCT00003460
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: BC-BT-13, NCT00003468
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: BC-BT-22, NCT00003476
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: BC-BT-23, NCT00003477
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: BC-BT-6, NCT00003535
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 20
Sponsor: Other
Protocol IDs: SIOP-EPENDYMOMA-99, AIEOP-EPENDYMOMA-99, CCLG-EPENDYMOMA-99, EU-99001, NCT00004224
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 30 at initial diagnosis
Sponsor: Other
Protocol IDs: CHP-693, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590
|
